Hutchmed (China) Limited announced its interim results for the six months ended June 30, 2024, with total revenue of 0.3057 billion US dollars, a 43% decrease compared to the same period last year. The company reiterated its full-year guidance for combined revenue from its oncology/immunology business, which is expected to be between 0.3 billion and 0.4 billion US dollars. FRUZAQLA® performed strongly in the US market, with sales of 0.1305 billion US dollars in the first half of the year. Net profit was 25.8 million US dollars, and cash and cash equivalents together with short-term investments amounted to 0.8025 billion US dollars. The company continues to advance key clinical projects and collaborate with international partners to accelerate the development and commercialization of new drugs.

Hutchmed (China) Limited announced its interim results for the six months ended June 30, 2024, with total revenue of 0.3057 billion US dollars, a 43% decrease compared to the same period last year. The company reiterated its full-year guidance for combined revenue from its oncology/immunology business, which is expected to be between 0.3 billion and 0.4 billion US dollars. FRUZAQLA® performed strongly in the US market, with sales of 0.1305 billion US dollars in the first half of the year. Net profit was 25.8 million US dollars, and cash and cash equivalents together with short-term investments amounted to 0.8025 billion US dollars. The company continues to advance key clinical projects and collaborate with international partners to accelerate the development and commercialization of new drugs.